Loading clinical trials...
Loading clinical trials...
This trial is conducted in Europe. The aim of this trial is to assess safety, tolerability, pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated drug on the body) of NNC0195-0092 (somapacitan) compared to placebo in healthy male subjects.
Age
20 - 45 years
Sex
MALE
Healthy Volunteers
No
Novo Nordisk Investigational Site
Neuss, Germany
Start Date
January 16, 2012
Primary Completion Date
March 18, 2013
Completion Date
March 18, 2013
Last Updated
December 24, 2020
105
ACTUAL participants
somapacitan
DRUG
placebo (somapacitan)
DRUG
Lead Sponsor
Novo Nordisk A/S
NCT06109935
NCT05230550
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT04970654